- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03710330
Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section
A Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing a Standard 1gm and a Low Dose 0.5gm IV Tranexamic Acid for the Control of Blood Loss at Elective Cesarean Section
The aim of the study is to determine, out of two doses (a standard and a low dose) compared to placebo, the optimal and minimal dose of an intravenously administered single bolus of tranexamic acid(TA) to reduce blood loss when administered during cesarean section(CS). Tranexamic acid is an antifibrinolytic agent, which causes a reversible and competitive blockade of the lysine binding sites on plasminogen molecules. It is a synthetic analog of the amino acid lysine and its action is to reduce blood loss. TA is widely in use in the field of obstetrics. Both antepartum and postpartum hemorrhage(PPH) is being treated by TA extensively. One study demonstrated for the first time that TA administered to women with overt PPH decreases blood loss and maternal morbidity. Prevention of PPH is another indication where TA has been used. Varied doses of TA ranging from 1 mg/kg to more than 100 mg/kg have been used in various surgeries. Even in studies involving CS, the doses used were either a bolus of 1 gm or 10 mg/kg intravenously.
The dose of 1 g or 10 mg/kg is commonly used prophylactically before CS, Because of the lack of data on lower doses and TA pharmacokinetics, a low 0.5-g dose should be tested.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
CS was carried out under subarachnoid block using 2-2.5 ml of 0.5% hyperbaric bupivacaine after an informed written consent. Blockade up to T4-T6 level was considered an adequate level of anesthesia. After delivery of the neonate, 20 unit of oxytocin in 500 ml normal saline will begive at the rate of 8 mU/min intravenously.
All consenting patients were recruited as a consecutive series to one of the three study groups of 120 patients each, based on block random allocation protocol. Neither the patient nor the investigator was aware of the group assignment. An anesthesiologist not related to the study prepared the drug for every patient.
Groups were labeled as follows:
Group one (120) - 5 ml of distilled water in 20 ml of 5% dextrose
Group two (120) - TA in the dose of I gm in 20 ml of 5% dextrose
Group three(120) - TA in the dose of 0.5gm in 20 ml of 5% dextrose.
The drug in all the groups was given intravenously over 20 min before skin incision.
Monitoring of the pulse rate, blood pressure, Pulse Oximetry (SpO2) and Electrocardiograph (ECG) was carried out every 2 min up to 10 min of starting the study drug; then every 5 min until the delivery of the baby and thereafter every 15 min until the end of the surgery. Blood loss was measured intra-operatively and postoperatively up to 24 h. All material such as sponges, mops, pads, and drapes were weighed with an electronic weighing scale before and at the end of surgery. A volume of blood in the suction bottle was considered only after the placental delivery, to exclude any amniotic fluid volume. The quantity of intra-operative blood loss (ml) = (weight of the abdominal swabs and drapes after CS - weight of materials prior to CS) + (the volume in the suction bottle after placental delivery in ml). Post-operative blood loss was measured by weighing and numbering the vaginal pads used by the patient after completion of CS 2 hourly up to 6 h and then 6 hourly up to 24 h.
Uterine contractility, placental separation, neonatal condition and any side effect caused by TA will be noted. Intramuscular methylergometrine would be used as a rescue uterotonic treatment when required. Post-operative hemoglobin, hematocrit, serum creatinine, and prothrombin time, values were recorded at 24 h. All the parturients were encouraged to start early leg exercises and ambulation in the post-operative period.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Aswan, Egypt, 81528
- Aswan University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: all pregnant women scheduled for elective cesarean -
Exclusion Criteria:
- Patients with a cardiac, hepatic, renal or thromboembolic disease.
patients had an allergy to tranexamic acid
. -patients who had received platelet antiaggregant such as Aspirin in the week before surgery
- patient refusing to be a participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
PLACEBO_COMPARATOR: normal saline
the patients receives 110 ml normal saline IV just before skin incision
|
110 ml normal saline IV just before skin incision
Other Names:
|
ACTIVE_COMPARATOR: 1gm tranexamic acid
1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
|
1 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
Other Names:
|
ACTIVE_COMPARATOR: 0.5 gm tranexamic acid
0.5 gm tranexamic acid (1 ampoule of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
|
0.5 gm tranexamic acid (2 ampoules of Capron 500 mg /5 ml; Cairo, Egypt) intravenous just before skin incision
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
intraoperative blood loss
Time Frame: during the operation
|
amount of blood loss during the operation
|
during the operation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
postoperative blood loss
Time Frame: 6 hours post operative
|
amount of blood loss 6 hours post operative
|
6 hours post operative
|
Number of participants need of uterotonic
Time Frame: 24 hours post operative
|
Number of participants need of extra uterotonic
|
24 hours post operative
|
Number of participants need blood transfusion
Time Frame: 24 hours post operative
|
Number of participants need of blood transfusion
|
24 hours post operative
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- aswu/276/7/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cesarean Section Complications
-
Assiut UniversityNot yet recruitingCesarean Section Complications | Cesarean Section Niche
-
Recep Tayyip Erdogan University Training and Research...CompletedCesarean Section Complications | Cesarean Section; DehiscenceTurkey
-
Ataturk UniversityUnknownCesarean Section Complications | Cesarean Section; Complications, Wound, Dehiscence | Cesarean Section, Repeated | Cesarean, Uterine Scar Thickness | Cesarean, Residual Myometrial ThicknessTurkey
-
University of CalgaryNot yet recruitingCesarean Section ComplicationsCanada
-
Peking University People's HospitalNot yet recruiting
-
Aswan University HospitalCompletedCesarean Section ComplicationsEgypt
-
Gaziosmanpasa Research and Education HospitalUnknownCesarean Section ComplicationsTurkey
-
Ain Shams UniversityUnknownCesarean Section ComplicationsEgypt
-
Mohamed Abdelrady MohamedCompletedCesarean Section ComplicationsEgypt
-
McGill University Health Centre/Research Institute...Thammasat UniversityUnknownCesarean Section ComplicationsCanada
Clinical Trials on normal saline
-
Texas Cardiac Arrhythmia Research FoundationSuspendedVentricular ArrythmiaUnited States
-
The Catholic University of KoreaCompleted
-
Ann & Robert H Lurie Children's Hospital of ChicagoWithdrawn
-
Texas Cardiac Arrhythmia Research FoundationCompleted
-
MemorialCare Health SystemCompletedLength of Labor | Second Stage of Labor | Intravenous Hydration of LaborUnited States
-
University of HaifaWestern Galilee Hospital-NahariyaRecruiting
-
McMaster UniversityGlaxoSmithKline; University of ManchesterRecruitingAsthma | Eosinophilic Bronchitis | Chronic CoughCanada
-
University of MichiganRadiological Society of North AmericaTerminated
-
Virginia Commonwealth UniversityUnited States Department of DefenseWithdrawn
-
Qassim UniversityCompletedApical Periodontitis | Post Operative Pain | Dental Pulp NecrosesSaudi Arabia